Low-dose cytarabine

Phase 3Small molecule

Bristol-Myers Squibb

Low-dose cytarabine is one of 102 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Myeloid NeoplasmActive, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Myelodysplastic SyndromesPreclinical

Active, not recruiting

Myeloid NeoplasmPhase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 3

50 2

Fludara

Sanofi

Phase 3

15 3

Vanflyta

Daiichi Sankyo

Phase 3

13 4

Peony

Takeda

Phase 3

6 5

Velcade

SShilpa Grover, MD, MPH

Phase 3

11 6

Tibsovo

SServier

Phase 3

8 7

Trisenox

CCephalon

Phase 3

7 8

Retin-a

VValeant Pharmaceuticals

Phase 3

2 9

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Lenograstim

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced Hematologic Malignancies

NCT04891757

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old

Unknown status·JJianxiang Wang·N/A·NCT02432911·300 enrolled

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02577406·319 enrolled

Myelodysplastic Syndromes1 trial

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Withdrawn·UUniversity of Florida·N/A·NCT03446638

AML1 trial

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Completed· Pfizer logo

Pfizer·Phase 2·NCT00528333·211 enrolled

Myeloid Neoplasm1 trial

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled

Advanced Hematologic Malignancies1 trial

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Active, not recruiting·FFoghorn Therapeutics Inc.·Phase 1·NCT04891757·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Low-dose cytarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-dose cytarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-dose cytarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Low-dose cytarabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Myelodysplastic Syndromes1 trial

AML1 trial

Myeloid Neoplasm1 trial

Advanced Hematologic Malignancies1 trial

References

Drug Info

Quick Facts

Related News